Tech Company Financing Transactions
Contraline Funding Round
On 6/2/2026, Contraline landed $92.5 million in Series B funding from BVF Partners, GV and Invus.
Transaction Overview
Company Name
Announced On
6/2/2026
Transaction Type
Venture Equity
Amount
$92,500,000
Round
Series B
Investors
BVF Partners (Lead Investor) (Iris van Alderwerelt van Rosenburgh)
RA Capital Management (Laura Stoppel)
Proceeds Purpose
Proceeds from the Series B financing will support the late-stage development of NES/T Gel, an investigational hormonal, reversible male contraceptive with first-in-class potential.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1216 Harris St
Charlottesville, VA 22903
USA
Charlottesville, VA 22903
USA
Phone
Website
Email Address
Overview
Contraline is inventing the future of male contraception. Contraceptives should fit seamlessly into the lives of couples. We are committed to making ours highly effective, long-lasting, and reversible. It's time to say goodbye to the anxiety and inconvenience of current methods.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Eisenfrats
Chief Medical Officer
Alex Pastuszak
Chief Technical Officer
Yelena Tropsha
Browse more venture capital transactions:
Prev: 6/2/2026: Mojro venture capital transaction
Next: 6/2/2026: NP Co. venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs